We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Endra said it will send the FDA additional limited confirmatory clinical data from a subset of its existing clinical evaluation sites, which it expects to receive this year. Read More
The FDA did not believe the company provided enough clinical evidence to support the expanded indication, as the system had not met the primary endpoints of its sebaceous hyperplasia study. Read More